Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Great perspective OE...thanks for bringing forth the realities of today's investment and trading mind sets.
GLTA!
3BB
Nice clip
Look forward to your return LJ. Would love to come join you!
Best idea all day long...take good care of yourself....
If I remember correctly 106/Russia and 54/US...total 160
Where have you been ogre? LOL If you get a chance catch up on all of yesterday's earlier posts. Lots of posts regarding this topic.
GLTA!
OPTEC Subsidiary Z2O Launches Vendor On-Boarding Program of Uber Type On-Demand App For Pandemic Sanitization & Cleaning In Austin Texas
CARLSBAD, CA / ACCESSWIRE / February 19, 2021 / OPTEC International, Inc. (OTC PINK:OPTI), a developer of UV and UV-C safety products using related advanced technologies specific to Personal Protection Equipment (PPE), today released the Z2O PRO App on the Apple store to begin marketing and onboarding for Z2O cleaning and sanitization professionals in the Austin, Texas area, with a particular focus on pandemic related services.
Z2O is now available for the onboarding of all cleaning and disinfecting service providers in the Austin, Texas area. This presents an opportunity for small, local cleaning companies and larger national franchise companies to enroll as a Z2O vendor in Austin, Texas. Providing a boost to cleaning businesses in the Austin area, Z2O will help assist locals in generating income during this most difficult time; not only with the pandemic, but with the current devastating weather conditions blanketing the state of Texas.
The Z2O PRO App is currently only available in the Apple Store, with availability in the Google Play Store coming in the very near future.
Z2O will be launching live in Austin, Texas on or before March 30tht 2021 for consumer services, with a target launch in Miami, Florida on or before March 22nd 2021, and several other locations shortly thereafter.
About Z2O
During these challenging times, there is a vital need to protect businesses and homes from harmful bacteria, viruses, and everything in between. Z2O is a new, on-demand app, delivering an effortless way to schedule cleaning and disinfecting services using smart devices, at the same time providing existing companies and starts ups new opportunities to create jobs and operate and expand business services. This is like the Uber of cleaning and disinfecting, offering the opportunity for the local workforce to have the ability to generate income for essential services that will help their local community as well as expand job opportunities for their employees and staff.
What the heck?
Fisker initiated with a Buy at R. F. Lafferty; tgt $23
3:29 PM ET 2/17/21 | Briefing.com
. R. F. Lafferty initiates FSR with a Buy and price target of $23. Analyst Jaime Perez commented, "Fisker Inc. (NYSE: FSR) is a California-based designer and developer of premium electric vehicles (EV). The company is developing the Fisker Ocean, an all-electric midsize luxury SUV for the consumer market with an MSRP between $37,499-$69,900. The market for EVs (electric vehicles) has increased dramatically over the past several years as customers migrate from fossil-fueled transportation to green energy transportation. The main reason for the higher demand for EVs is climate change concerns among consumers. However, consumers have been slow to adopt EVs primarily because of driving distance limitations and extended battery charging time. The goal of the company is to become a "premium automaker producing more than 100,000 units". Fisker will introduce a prototype of the Ocean all-electric SUV in mid-2021. Then, the company will launch production of the Ocean in late 2022. We are initiating coverage of Fisker Inc. (NYSE: FSR) with a Buy rating and a $23 per share price target. Our price target is based on 7.5x EV/EBITDA multiple and 2023E Sales of $310 million."
Hello AITX followers. Apologies, I am new to the company. Have spent much of the day doing DD. Looks like a worthwhile buy to the plus side, clear upward trend. Fairly certain the most recent gaps will have to be filled thought (IMHO)...I could very well be totally wrong. Doubt mm will let it run without it though....unless talks with tesla prove more substantive in the relative near term and of course any other Fortune 100 announcement. Anyhow, I'm excited to watch what happens over the next several months.
P.S. If anyone has any additional dd other than IHUB read, Reddit and of course the most recent PR's published please PM me. I look appreciate as much insight as possible.
Thank you in advance!
3BB
Love it Coop!
Fortunately I'm in at most of my holdings bottoms. Just hard to see significance of down versus up days. I feel good about the DD and buy in points. Tomorrow is a new day and hopefully the sun will be shining!
Love your posts Prov...
3BB
Mine too...not a good Thursday for my portfolio. Always springs back though. Solid DD and know what you own!
Happy Days to Come!
3BB
Any time Lily....Hope you are staying warm!
IPI-BRIc-201
Protocol name
Double-blind, placebo-controlled, randomized, multicenter Phase II study to evaluate the efficacy and safety of Brilacidin in patients hospitalized with COVID-19
Therapeutic area
Anesthesiology and resuscitation, Infectious diseases, Oncology, Therapy (general), Surgery, Cardiology, Pulmonology, Toxicology
CI start and end date
12/17/2020 - 03/31/2021
RCT number and date
No. 705 dated 12/17/2020
Organization conducting CT
Innovation Pharmaceuticals Inc. (Innovation Pharmaceuticals Inc.)
Drug name
Brilacidin
Dosage form and dosage
solution for intravenous administration, 50 mg / ml
Cities
Barnaul, Kirovsk, Moscow, Nizhny Novgorod, Ryazan, St. Petersburg, Saratov, Yaroslavl
Developer country
USA
Organization involved by the drug developer
IPharma LLC, 143026, Moscow, the territory of the Skolkovo innovation center, st. Nobel, 7, Russia
CI phase
II
KI type
IMCI
The purpose of CI
assessment of the efficacy and safety of Brilacidin in patients hospitalized with COVID-19
Number of medical institutions
20
Number of patients
106
Advantages of clinical trials in Russia
There are a multitude of factors that influence companies decisions to open clinical operations in Russia for all types of clinical trials: some of them are
Russia Clinical Trial Advantages
Data acceptance
Patient pool
Relevant investigators’ expertise, and
Cost-efficiency
Data acceptance
With adherence to global standards and regulations observed in clinical studies, The FDA and EMA accept data from such clinical trials in Russia.
Patient pool
The Russian hierarchical health care system contains a large number of health care facilities across the country which provides substantial access to various patient populations and enables rapid recruitment of study participants. Genetic diversity and high urban proportion
Investigators expertise
Access to educated, experienced, and compliant investigators who are motivated to participate in clinical trials to advance new drug development. There are GCP trained and certified Investigative Sites generating high-quality data.
Lower Costs
Russia offers lower costs for conducting clinical trials as compared to the US and Western Europe. Some of the experts have claimed that compared to the US, Russian sites offer approximately 30-60% savings to sponsors depending on the complexity of the study, study-specific procedures, patient population, and etc.
A "schedule 13G" filing is reserved for "passive investors", or those who do not intend to "exert control" in a company.
Schedule 13D filings are reserved for people or companies who may be interested in agitating for some kind of a change at the company, whereas "passive investors" are just that - passive.
What triggers a 13G filing?
Institutional investors must file a Schedule 13G within 45 days after the calendar year in which the investor holds more than 5% as of the year end or within 10 days after the end of the first month in which the person's beneficial ownership exceeds 10% of the class of equity securities computed as of the end of the....
When should we file Form 13G?
The initial Schedule 13G is due within 45 calendar days after the calendar year in which the person becomes obligated to file and amendments are due within 45 calendar days after the end of each calendar year thereafter to report any change in the information contained in the Schedule 13G.
Also read maxinvest's post 346724
IPIX
Interesting articles surfacing. Trying to piece information together. Read below...part about 10-k delay "due date relating to clinical trials in the United States and Russia"
PART III — NARRATIVE
State below in reasonable detail why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-CEN, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period.
Innovation Pharmaceuticals Inc. (the “Registrant”) was unable, without unreasonable effort or expense, to file its Quarterly Report on Form 10-Q (the “Quarterly Report”) for the period ended December 31, 2020 (the “Reporting Period”) by the February 16, 2021 filing due date applicable to non-accelerated filers due to a delay experienced by the Registrant in preparing disclosure relating to recent developments regarding clinical trials for the Registrant’s lead drug compound, and in particular, developments on or around the filing due date relating to clinical trials in the United States and Russia. The Registrant anticipates that it will file the Quarterly Report no later than the fifth calendar day following the prescribed filing due date.
Russia is planning to present an "antidote" to Covid-19. It is expected to be more than 99% effective. This was stated by the head of the Federal Medical and Biological Agency Veronika Skvortsova, according to the website of the Russian government.
It is also planned to release one more unique medicine.
Related: UK approves AstraZeneca vaccine against Covid-19
"Both are unique and have no analogues in the world. The drug that I would like to talk about is the first etiotropic drug that directly affects the virus. In fact, it is an antidote to coronavirus infection," Veronika Skvortsova said.
Related: Ukraine needs to develop rules for coexistence with Russia as neighbor, - Foreign Minister
The effectiveness of this "antidote" in preclinical trials was up to 99%. If clinical trials are successful, it will be the world's first direct-acting antiviral drug.
The second drug is being developed to treat severe complications of coronavirus infection - a cytokine storm or an abnormal response of the immune system. This drug has already passed clinical trials and is at the last stage of registration.
PART III — NARRATIVE
State below in reasonable detail why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-CEN, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period.
Innovation Pharmaceuticals Inc. (the “Registrant”) was unable, without unreasonable effort or expense, to file its Quarterly Report on Form 10-Q (the “Quarterly Report”) for the period ended December 31, 2020 (the “Reporting Period”) by the February 16, 2021 filing due date applicable to non-accelerated filers due to a delay experienced by the Registrant in preparing disclosure relating to recent developments regarding clinical trials for the Registrant’s lead drug compound, and in particular, developments on or around the filing due date relating to clinical trials in the United States and Russia. The Registrant anticipates that it will file the Quarterly Report no later than the fifth calendar day following the prescribed filing due date.
Daily volume has significantly increase since JAN 15 to present.
Competition
The Global Supply Chain management area has many different entities, all competing. Some are very large. However, our model is significantly different from most of the providers already operating.
To be successful in the global supply chain management area, a company must be involved in planning the function of the entire process, from start to finish, or end to end. We intend to concentrate our model on the cannabis, nutraceutical, pharmaceutical and cosmetic areas. We believe this makes our approach unique and distinguishable at this time.
There is no guarantee that a larger, more fully funded, company will determine to seek to gain access to the same business.
Intellectual Property
Our Global3pl SAAS Platform is a proprietary software developed by the Company. The SaaS-based platform ecosystem will fully integrate all aspects of the Cannagistics operations, from receiving raw materials for clients, through product manufacturing, document compliance, distribution, and shelf-life batch tracking.
We have plans to develop a GMP certified biotech lab in Malta with a fundamental skill in initially the cosmetic and then potentially the medicinal, nutraceutical and cannabis/hemp/CBD industries. Our plan is to have this Malta lab cater to customers in the EU. We also plan to potentially have other facilities that will cover our target customers in the US, Canada and Columbia, potentially located in Baton Rouge, Toronto and Bogotá, respectively.
If we are successful in fully developing such capabilities we intend to seek out and employ a team of a multidisciplinary professionals in the pharmaceutical, nutraceutical and over the counter industries, and utilize complex supply chain and logistics management, unique technology and intellectual property. Cannagistics’ Lab’s purpose is to add value and offer a progress proposal to the Malta medicinal cannabis industry, based on its interest to support, educate, take advantage of and focus on the development of potentially breakthrough medicinal cannabis products with different therapeutic uses in patients around the world to whom science and traditional medicine simply could not reach. Such products will be subject to testing and certification from various governmental agencies, which may be a difficult expensive and time-consuming process. Our vision and knowledge will potentially focus on GMP biopharmaceutical cannabis-based medicines, - with the highest standards starting from the raw material - for multiple applications in patients, using latest technology, ancestral knowledge, scientific studies, with an exceptional team of research and development following the strictest standards and good distribution practices for export and national use.
This post should be pinned. Best advice for all to follow and not forget.
ETRADE looking to dump 1mm shares at .01437
I'm sure this question has already been asked and answered so apologies in advance for asking again....
....any idea when we might find out about EUA approval status?
TIA
3BB
Is there a link between Carnegie and Renewal Fuels, Inc...RNWF? Somebody on Twitter posted to his twitter feed....JC
TIA,
3Bb
I'm holding tight for this ride. The upside potential compared to the downside side risk isn't that bad from previous buy-in value. Big picture is there is way more upside than downside potential from where I'm sure most of us hopped in at.
JMHO FWIS
https://finance.yahoo.com/news/optec-international-publishes-dec-31st-171000915.html
OPTEC International Publishes Dec 31st, 2020 Quarterly Financial Report Exceeding Expectations Showing Revenue Increase of 1000% From Previous Quarter
CARLSBAD, CA / ACCESSWIRE / February 17, 2021 / OPTEC International, Inc. (OTC PINK:OPTI), a developer of UV and UV-C safety products using related advanced technologies specific to Personal Protection Equipment (PPE), today announced the company's December 31st, 2020 Quarterly Financial Report with over 1000% increase in revenue from the previous quarter. This was achieved by strong and larger transaction volumes during the significant reported increase in Pandemic cases globally.
The significant increase in revenues exceeded $11M for this period and generated a net income of approximately $7.38M increasing shareholder equity to $17M.
Company CEO Roger Pawson commented "As a result of the growth the company has acquired an additional 17,298 sq. feet warehouse and distribution center within close proximity to the company's existing two facilities. OPTEC takes possession of the new facility March 1st, 2021".
Mr. Pawson further stated, "Upon full completion of the company's $2B+ PPE and Medical supply contract , the company intends to use the profits to launch a stock buyback program and continue the goal of up listing to the NASDAQ Exchange".
Dec 31st 2020, Financial Report Link: https://backend.otcmarkets.com/otcapi/company/financial-report/271185/content
Recent Company Announcement:
OPTEC announced the addition of Antigen & Antibody Rapid-Test Kits with 10 Minute Results to the company's PPE Inventory for global distribution. The Rapid-Test Kits are manufactured in the USA and comply with the specific requirements for Rapid-Testing within the current FDA and CDC guidelines.
OPTEC Acquires Z2O the "Uber of Cleaning & Sterilization APP". www.Z2O.com
OPTEC Appointments Kyle McGowan Former CDC Chief of Staff and Amanda Campbell Former Deputy CDC Chief of Staff to the company's Advisory Board.
About OPTEC International, Inc. With Locations in Carlsbad and Vista, California, OPTEC International is a developer and manufacturer of electronic LED, Ultraviolet (UV) & UV-C safety products and related advanced technologies and PPE (Personal Protection Equipment) products. The company's Safe-Scan product line is being launched at a time when HR directors and facilities managers are experiencing extreme concern with respect to keeping environments safe during the global pandemic crisis and the safe reopening of the U.S. economy. For more information, visit: www.optecintl.com
Agree...Patience required
200 dma is .0007
100 dma is .0012
50 dma is .0022
25 dma is .0032
Craziness....more than 44mm traded thus far.
Not I.....I’m long haul holder/investor. My thought in posting pm is simply to see strength in daily open. However I do see your broader point crazyeye. Moving forward I’ll respectfully reframe.
3BB
Something is brewing
https://marketglobalist.com/2021/02/17/regardless-of-many-stocks-being-in-the-red-social-life-network-inc-wdlf-appears-to-have-promise/
FINANCIAL MARKETSPENNY STOCKS
February 17, 2021
Updated: 1 hour ago
Regardless of Many Stocks Being In the Red, Social Life Network Inc (WDLF) Appears to Have Promise
By
Nora Barnes
Share Facebook Twitter Pinterest
Social Life Network Inc. [WDLF] closed at $0.0345 on Tuesday, up 32.69%, and has been trading in a day range of $0.0395 to $0.0280. With over 486.59M shares traded during the month, WDLF surged more than 1.226.92% last month.
Sponsored
Social Life Network Inc. [WDLF] is a Technology Business Incubator (TBI), providing seed funding for technology startups along with technical assistance, legal guidance, and executive leadership. This helps startup founders develop their business models, perfect the business model, and grow their network users. With its services, Company aims to incubate companies that it will eventually sell or take public. The company’s revenue model entails a 5% royalty from profits generated by our licensees and a 15% ownership stake in their Company after a liquidity event. Three licensees of Social Life are going public on NASDAQ or the NYSE as of 4th quarter 2020.
Read More
Investing in the Gaming Industry; 3 of the Best Gaming Stocks
Top 3 Social Media Stocks to Watch for in 2021
Last Announcements
April 8, 2020 – It was announced by Social Life Network, Inc. (OTC PINK: WDLF). They held their shareholder update on April 7, which included an update on their Form 10-K filings for 2018 and a prospectus for their licensee division’s future growth. MjLink filed a form 1-A amendment on March 31, 2020.
March 30, 2020 – Social Life Network, Inc. (WDLF) announced that it would move its shareholder update call scheduled for March 31 to April 7 instead.
On February 12, 2020, MjLink.com, Inc., a wholly-owned subsidiary of Social Life Network, filed their Form 1-A with the securities broker. A series of delays has caused essential updates that were previously expected before the March 31 call to be put on hold.
https://finance.yahoo.com/news/pharmather-announces-sale-psilocybin-program-140200533.html
PharmaTher Announces Sale of Psilocybin Program
Newscope Capital Co
TORONTO, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Newscope Capital Corporation (CSE: PHRM) (OTCQB: PHRRF), who through its wholly-owned subsidiary, PharmaTher Inc. (“PharmaTher” or the “Company”), is a specialty life sciences company focused on the research and development of psychedelic pharmaceuticals, is pleased to announce that, further to its press release dated December 21, 2020, it has entered into an asset purchase agreement (the “Agreement”) with Revive Therapeutics Ltd. (“Revive”) (CSE: RVV, USA: RVVTF) to sell the full rights to PharmaTher’s intellectual property (the “Acquired Assets”) pertaining to psilocybin (the “Acquisition”).
Pursuant to the Agreement, Revive will pay aggregate consideration of up to CAD $10 million (the “Purchase Price”). The Purchase Price will be satisfied as follows: (i) $3 million in cash will be paid on the closing date; (ii) $4 million will be satisfied through the issuance of securities in the capital of Revive and (iii) up to $3 million, in either cash or securities in the capital of Revive, in the event that Revive achieves certain milestones, which include Revive obtaining FDA orphan drug designation for psilocybin in the treatment of stroke, traumatic brain injury, or cancer, the commencement of a Phase 2 clinical trial and the regulatory filing for market authorization, such as U.S. Food and Drug Administration (“FDA”) approval. In addition to the Purchase Price, Revive will also pay Newscope Capital Corporation a low single digit royalty on all future net sales of products derived from the Acquired Assets.
“We are very pleased with the sale of our psilocybin program as it pertains to the intellectual property and research for the use of psilocybin in the treatment of stroke, traumatic brain injury and cancer to Revive as it provides us with non-dilutive funding to advance the clinical development of ketamine in the treatment of Parkinson’s disease, KETABET™ in the treatment of depression and the development of our proprietary microneedle delivery technologies to deliver psychedelic pharmaceuticals including ketamine, esketamine, psilocybin, MDMA, LSD and DMT for various mental health, neurological and pain disorders,” said Fabio Chianelli, CEO of PharmaTher. “We are now in a strong position to unlock the value of our unique psychedelic-based product pipeline and microneedle delivery technologies, and to advance our lead program ketamine to treat Parkinson’s disease towards FDA Phase 2 clinical trials.”
PM .0369 - .038
Interested to know....Who on this board is GTSM on the sell for roughly 873k shares...JC